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Mammalian platelets contain an array of antimicrobial peptides, termed platelet microbicidal proteins (PMPs). Human and rabbit PMPs include
known chemokines, such as platelet factor-4 (hPF-4); PMP-1 is the rabbit orthologue of hPF-4. Chemokines that also exert direct antimicrobial
activity have been termed kinocidins. A consensus peptide domain library representing mammalian PF-4 family members was analyzed to define
structural domains contributing to antimicrobial activity against a panel of human pathogens. Secondary conformations were assessed by circular
dichroism spectrometry, and molecular modeling was employed to investigate structural correlates of antimicrobial efficacy. Antimicrobial activity
against isogenic peptide-susceptible or -resistant Staphylococcus aureus, Salmonella typhimurium, and Candida albicans strain pairs mapped to
the C-terminal hemimer (38–74) and modular domains thereof (49–63 and 60–74). Increasing electrostatic charge and steric bulk were general
correlates of efficacy. Structural data corroborated spatial distribution of charge, steric bulk and putative secondary structure with organism-
specific efficacy. Microbicidal efficacies of the cPMP antimicrobial hemimer and C-terminal peptide (60–74) were retained in a complex human-
blood biomatrix assay. Collectively, these results suggest that modular determinants arising from structural components acting independently and
cooperatively govern the antimicrobial functions of PF-4 family kinocidins against specific target pathogens.
© 2006 Elsevier B.V. All rights reserved.Keywords: Antimicrobial; Peptide; Structure; Platelet; Kinocidin; Chemokine1. Introduction
Antimicrobial peptides are typically small, cationic and
amphipathic molecular effectors of innate immunity present inAbbreviations: PF-4, platelet factor 4; PMP, platelet microbicidal protein;
PBP, platelet basic protein; CTAP-3, connective tissue-activating peptide 3;
β-TG, beta thromboglobulin; NAP-2, neutrophil activating peptide-2; CXC,
cysteine–X–cysteine; CC, cysteine–cysteine; CXCR, CXC receptor; CCR, CC
receptor; YNB, yeast nitrogen broth; CD, circular dichroism; F-moc
(9-fluorenyl-methyloxycarbonyl); TFA, trifluoroacetic acid; MALDI-TOF,
matrix-assisted laser desorption ionization time-of-flight; PIPES, piperazine-N,
N′-bis`2-ethanesulfonic acid]; r2, linear correlation coefficient; Da, daltons and
standard single letter codes for amino acids
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doi:10.1016/j.bbamem.2006.11.010organisms across the phylogenetic spectrum. Recently, a new
group of antimicrobial peptides has been identified among
classical cytokines: microbicidal chemokines [1–5]. Chemo-
kines that exert direct microbicidal activity have been termed
kinocidins [6,7]. Kinocidins are typically larger and have greater
structural complexity than classical antimicrobial peptides.
Moreover, distinct structural domains in kinocidins are hypothe-
sized to confer complementary microbicidal and leukocyte-
potentiating functions [7,8]. Thus, kinocidins represent multi-
functional immune effector molecules that coordinate molecular
and cellular host defense against infection.
Relative to most classical antimicrobial peptides, kinocidins
have comparable antimicrobial spectra and efficacy [9,10].
Traditional antimicrobial peptides and kinocidins are also
analogous in their rapid induction, mobilization, or accumula-
tion in response to signals of infection [11–18]. However, in
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which are confined within phagocytes or expressed on mucosa,
kinocidins are commonly elaborated directly in the bloodstream.
These considerations are consistent with the concept that
kinocidins exert comparatively less host toxicity than many
antimicrobial peptides [9,19]. Therefore, understanding critical
structure–activity relationships in kinocidins will clarify their
roles in host defense, and may assist in design of novel anti-
infective therapeutics that are efficacious against increasingly
antibiotic-resistant pathogens, and have minimal concomitant
host cytotoxicity.
Recent studies offer general aspects of sequence and
biochemical properties that may contribute to kinocidin
antimicrobial efficacy [2,5–7,20]. However, specific structural
determinants that confer their antibacterial versus antifungal
properties, or their efficacies against strains differing in anti-
microbial peptide susceptibility phenotypes, have not been
defined. With these goals in mind, the current studies applied
biochemical and biophysical techniques, integrated with quan-
titative molecular modeling, to uncover the principal determi-
nants of antimicrobial activity in the PF-4 family of kinocidins.
2. Materials and methods
2.1. Microorganisms
Strain pairs of three prototypic human pathogens were used in this
investigation: Staphylococcus aureus strains ISP479C and ISP479R (Gram-
positive bacterium; [20]); Salmonella typhimurium strains 14028 and m5996s
(Gram-negative bacterium; [21]); and Candida albicans strains 36082S and
36082R (fungus; [22]). Each of these well-characterized pairs have been used
previously to evaluate antimicrobial peptide activity, and include isogenic
counterparts that exhibit relative susceptible (S) or resistant (R) phenotypes toTable 1
Comparative sequences of PF-4 family kinocidins, cPMP, and its peptide library
hPF-4 and PMP-1 are predominant antimicrobial peptide orthologues in rabbit and h
gi|62739642), hPF-4var (GenBank Code, gi|130306), PMP-1 and its variant Asp
database. Sequences of PMP-1 variants were determined from multiple protein sequ
variants likely represent allelic polymorphisms. Principal structure domains are indica
and 15-mer peptide library. As detailed in the text, the N-terminal domains contain
the multidimensional γ-core signature present in a diverse range of cysteine-stabi
amphiphilic α-helical motif common to many classical antimicrobial peptides. Thus,one or more antimicrobial peptides. Organisms were cultured in brain heart
infusion broth (BHI; Difco Laboratories, Detroit, MI; 37 °C with agitation) or
yeast nitrogen broth (YNB; Difco; 30 °C with agitation) to logarithmic phase,
and prepared as previously described [6]. In brief, cells were harvested by
centrifugation, washed twice in appropriate assay buffer (below), sonicated
briefly to ensure dispersion, and adjusted by optical density to desired inocula.
Concentrations of final inocula were verified by quantitative culture.
2.2. Peptide synthesis
Previous studies have demonstrated that PMP-1 and hPF-4 contain three
analogous structural domains [7]: (1) a relatively unstructured N-terminal
domain containing the CXCmotif characteristic ofα-chemokines; (2) a highlyα-
helical and cationic C-terminal domain reflecting strong amphipathic propensity
similar to many antimicrobial peptides; and (3) an interposing domain comprised
of anti-parallel β-sheet domains, two of which constitute an iteration of the γ-
core motif of cysteine-stabilized antimicrobial peptides [6]. A consensus peptide
(cPMP) and its library were designed to reflect such structural domains in hPF-4,
PMP-1, and variants thereof. A peptide library was synthesized to assess
potential antimicrobial correlates associated with specific domains or broader
regions in PF-4 family members (Table 1). In cPMP, residues were assigned to
prioritize antimicrobial activity and increase the probability for molecular
modeling (below) to reveal meaningful correlates of activity. The library was
comprised of domains 15 amino acids in length, overlapping by 3 residues
each, and larger peptides representing one-half of the full-length molecules
(hemimers), encompassing the amino-(residues 1–37) and carboxy-terminal
regions (residues 38–74; Fig. 1). A novel congener modeled to reflect key
physicochemical properties of PF-4 family helical domains (RP-1; ALYK-
KFKKKLLKSLKRLG; [23]) was also evaluated for efficacy in parallel to the
above peptide panel. All peptides were synthesized by automated F-moc
(9-fluorenyl-methyloxycarbonyl) chemistry. Classical antimicrobial peptides
(human neutrophil defensin HNP-1; protamine; gramicidin D; Peptides
International, Louisville, KY) were assayed as comparators.
2.3. Peptide purification and authentication
Native PMP-1 and synthetic cPMP walkthrough peptides were purified as
previously described using reversed-phase HPLC [2]. Purified peptides wereuman platelets, respectively. Amino acid sequences for hPF-4 (GenBank Code
PMP-1 [GenBank Code gi|42411026; [7]] are available through the NCBI
encing reactions (Yeaman et al., unpublished). As with human PF-4, the PMP-1
ted for each full-length sequence, as well as the cPMP hemimer (1–37 and 38–74)
CXC chemokine motifs, the interposing regions contain a kinocidin iteration of
lized host defense peptides, and the C-terminal domains comprise a hallmark
cPMP represents a logical composite of the PF-4 family of kinocidin sequences.
Fig. 1. Comparative structural features of cPMP and its library peptides.
Secondary structure data were determined experimentally from independent CD
spectra of each peptide as detailed in Materials and methods, and expressed as
percent of structure. Data refer to corresponding hemimer or walkthrough
domains, indicated in red to identify positioning within the full-length molecule.
Cysteine bridges are indicated in yellow. Three-dimensional structures of full
length and domain peptides were modeled as described previously [7]. A close
agreement was identified between the modeled and experimentally-determined
structural characteristics.
Fig. 2. Comparative circular dichroic spectra of antimicrobial cPMP domains
13–27 (red line), 49–63 (blue line), and 60–74 (black line). Note the double
dichroic minima of domain 60–74 at 208 and 218 nm, corresponding to a highly
ordered α-helical conformation. By comparison, domain 49–63 is considerably
less helical, and contains substantially greater sheeting and turn propensity,
reflecting its relative position within the greater topological configuration of the
molecule. Domain 13–27 has more equivalent helical, sheeting, and turn
propensities, with considerably more unstructured aspects. These comparisons
illustrate the concept that, while all three domains have identical length and
exhibit similar mass and net cationic charge, they have diverse secondary
structure propensities that contribute to their distinct antimicrobial efficacies and
spectra.
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(MALDI-TOF; PerSeptive Biosystems, Foster City, CA) or electrospray (ES;
Perkin-Elmer Corp., Boston, MA) spectrometry. Experimentally determined
masses were within standard confidence intervals for calculated masses (<±0.1%
or <±0.04% of peptide molecular weight for MALDI-TOF or ES mass
spectrometry, respectively). Peptide composition and quantity were also verified
by amino acid analyses (Molecular Structure Facility, University of California,
Davis). PMP-1 was confirmed for expected antimicrobial activity by a standard
radial diffusion assay [7], and all peptides were lyophilized and stored at − 70 °C
until use. Highly-purified human platelet factor-4 (hPF-4) was obtained
commercially (Biosource International, Camarillo, CA) (Fig. 2).
2.4. Assays for antimicrobial efficacy
Complementary methods were used to assay antimicrobial efficacy of
peptides in vitro against the panel of study strains.
2.4.1. Solid phase diffusion assay
A modified solid-phase diffusion assay [6] afforded specific advantages
important to this study: (i) it allowed direct comparison of peptide activities
versus distinct organisms; and (ii) it yielded continuous (non-quantal) data,
facilitating computational modeling to examine structure-activity relationships.
The assay media were buffered to pH 7.5 using PIPES (piperazine-N,N′-bis[2-
ethanesulfonic acid] (Sigma). Following incubation at 37 °C (18 h for bacteria,
36 h for C. albicans), the diameter zones of inhibition surrounding wells were
measured. All peptide antimicrobial assays were performed a minimum of three
independent times.
2.4.2. Solution-phase assay
A solution-phase assay was also used to evaluate microbicidal efficacy of
study peptides. Organisms were prepared as above in PIPES buffer, but lacking
agarose. Peptides (range, 1.25–5 nmol/ml) were introduced into buffer
containing organisms to achieve final inocula of 1×106 CFU/ml. Followingincubation for 1 h at 37 °C, aliquots were serially diluted and plated in triplicate
for quantitative enumeration.
2.4.3. Biomatrix assay
Antimicrobial activities of cPMP38–74 and cPMP60–74 were assessed in
human whole blood and homologous plasma and serum fractions as we have
detailed previously [21]. The target strain of Escherichia coli is resistant to
serum, ideal for use in assessing peptide antimicrobial activity in blood and
blood-derived matrices [21]. Peptide (concentration range 1.0–50.0 μg/ml) was
added either simultaneously with the microorganism (10 μl; 105 CFU/ml), or 2 h
prior to the organism to achieve a pre-incubation period in the biomatrix.
Mixtures were incubated with constant agitation for 2 h at 37 °C. After
incubation, aliquots were diluted, quantitatively cultured in triplicate onto blood
agar, and surviving organisms enumerated as CFU/ml. Experiments were
performed a minimum of two independent times on different days and with
different blood donor sources.
2.5. Spectrometric assessment of peptide structure
Secondary structures of cPMP library peptides were assessed by circular
dichroism (CD) as previously detailed [22]. The CD spectra were deconvoluted
into helix, β-sheet, turn, and extended structures using Selcon [23] accessed by
on-line Dichroweb [24] interface (cryst.bbk.ac.uk/cdweb), and interpreted as
previously described [22,25,26].
2.6. Computational modeling
To complement structure analyses, 3-D models of full-length cPMP and
library peptides were created using complementary methods, as previously
described [7]. In brief, homology techniques (SWISS-MODEL, BLASTP2) were
Table 2
Physicochemical profile of cPMP and library peptides
Domain Physicochemical characteristics
Length Mass a pI b Charge c DC
d MH
e Hydropathy f
cPMP 74 8167 9.0 +6 +0.08 0.86 −16.42
1–37 37 4019 6.0 −1 −0.03 1.02 −13.42
38–74 37 4166 9.7 +7 +0.19 0.69 −2.38
1–15 15 1634 4.0 −4 −0.27 1.78 −11.82
13–27 15 1712 9.3 +3 +0.20 0.38 −0.59
25–39 15 1662 7.6 +1 +0.07 0.99 −2.9
37–51 15 1525 8.9 +2 +0.13 0.83 −0.62
49–63 15 1706 8.8 +2 +0.13 3.52 −2.55
60–74 15 1746 9.8 +4 +0.27 3.56 −3.42
Note the polarization of electrostatic charge and mass in the terminal domains.
For example, despite being equal in residue number and similar in hydrophobic
moment, the N-terminal domains 1–15 and C-terminal domains 60–74 have
substantially different mass, as well as opposing charge, charge density, and
hydropathy. With the exception of charge, large differences in these parameters
among distinct domains are attenuated in context of their greater respective
hemimer.
a Average mass (Da).
b Isoelectric point estimated in aqueous phase.
c Net charge as calculated at pH 7.
d Average charge density calculated as net charge c/number of residues
(length).
e Mean hydrophobic moment.
f Partition coefficient hydropathy (hydrophobic potential as implemented in
HINT).
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similarities in the ExNRL-3D database [27,28]. In parallel, the SIM alignment
algorithm [29] prioritized templates with greatest sequence identity. ProModII
was used to conduct primary and refined match analyses. In a complementaryTable 3
Comparative antimicrobial efficacies of PMP-1, hPF-4, and the cPMP library peptid
Organism S. aureus a
Strain ISP479C ISP4
Peptide Zone of inhibition (mm)
PMP-1 6.5 3.5
hPF-4 5.5 3.5
Hemimers 1–37 0.5 d 0.5
38–74 6.2 5.0
Walkthrough domains 1–15 0.5 0.5
13–27 0.9 1.1
25–39 0.5 0.5
37–51 0.5 0.5
49–63 2.8 1.9
60–74 5.6 2.9
Novel agent RP-1 6.0 5.0
Classical peptides HNP-1 6.5 ND
Protamine 7.5 7.5
Gramicidin D 7.8 7.0
Note a predominance of broad spectrum antimicrobial efficacy corresponding to
Interestingly, specific activity versus S. typhimurium corresponds to the more N-ter
largely mitigated in context of its N-terminal hemimer (1–37).
Mean data from a minimum of 2 experiments performed independently with reprod
a S. aureus pair: ISP479C (peptide-susceptible; C) and ISP479R (-resistant; R).
b S. typhimurium pair: 5996s (peptide-susceptible; s) and 14028 (-resistant).
c C. albicans pair: 36082S (peptide-susceptible; S) and 36082R (-resistant; R).
d Limit of detection, 0.5 mm.
e ND, not determined.strategy, amino acid sequenceswere converted to putative solution conformations
by sequence homology [Composer; [30]] and threading methods [Matchmaker
[31], Gene-Fold [32]] implementedwith SYBYL software (Tripos Associates, St.
Louis, MO). Conformers of target peptides were refined using the AMBER95
force field and molecular dynamics [33]. Preferred conformations were
determined from extended molecular dynamics, with torsion angles of peptide
bonds adjusted to 180±15 degrees withminimal constraints (0.4 kJ). The specific
physicochemical properties of peptides were visualized by MOLCAD [34] and
HINT [35], superimposed upon backbone trajectories or projected onto water-
accessible molecular surfaces. Molecular dynamics were executed without
constraints, or with the α-helical region constrained by applying a 0.4 kJ penalty
to canonical Ramachandran ϕ and ψ angles. Global energy was minimized after
removal of constraints and aggregates. Model conformations were prioritized
based on integrated criteria as appropriate: (i) favorable strain energy (molecular
mechanics); (ii) empirical positional (pseudo) energy functions; and (iii)
preservation of spatial conservation of cysteine pairs [7].
2.7. Statistical evaluation
Differences in results of independent assays of strain peptide susceptibility
were analyzed using the Wilcoxon Rank Sum test with Bonferroni correction for
multiple comparisons. Linear correlation coefficients (r2) were determined with
the statistical package KYPlot (version 2.0).3. Results
3.1. Peptide library
Comparative sequences of PF-4 family members, cPMP, and
its library peptides are summarized in Table 1. Native and
synthetic peptides were purified to >95% homogeneity by RP-
HPLC (data not shown), and authenticated to have masses
within ±0.1% of calculated values (Table 2).es
S. typhimurium b C. albicans c
79R 5996s 14028 36082S 36082R
8.5 4.5 4.0 2.5
7.0 5.0 3.5 2.0
1.5 0.5 0.5 0.5
9.3 5.4 5.0 4.1
0.5 0.5 0.5 0.5
7.2 2.4 2.6 1.6
0.9 0.5 0.8 0.5
0.5 0.5 0.5 0.5
8.8 4.0 5.3 5.7
8.8 5.5 5.1 4.6
6.0 6.0 3.0 4.0
e 5.3 ND 5.5 5.3
5.5 5.8 12.8 6.3
2.3 2.0 0.5 2.5
the C-terminal hemimer (38–74) and its subdomains (49–63 and 60–74).
minal proximate domain 13–27. However, the efficacy of this latter domain is
ucible results (standard error of the mean<5%).
Fig. 3. Solution-phase microbicidal activities of cPMP38–74 and RP-1. One
million CFU of the indicated microorganism per milliliter were incubated with
peptide (range, 1.25–5.0 nmol/ml) in PIPES (10.0 mM, pH 7.5) for 1 h at 37 °C.
Surviving CFU were enumerated and indicated as change from the initial log10
CFU. ◊, S. aureusATCC 27217;•, S. typhimurium strain 5996s;□,C. albicans
ATCC 36082. Data are means±SD (minimum n=2).
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The amino acid compositions and overall biochemical
attributes of hPF-4 and PMP-1 have been compared previously
[7]. The relative biochemical features of cPMP and its library
peptides are summarized in Table 2. Molecular masses of the
hemimers were comparable (4019 Da [N-terminal 1–37] versus
4166 Da [C-terminal]), as were masses of individual walk-
through 15-mer peptides (range, 1525 Da [37–51] to 1746 Da
[60–74]). In contrast, electrostatic charge, steric bulk, and
hydropathy varied among structural domains, and corresponded
to native molecules. Consistent with this concept, greatest
cationic charge density and pI localized to the C-terminal
hemimer, and specifically to the C-terminal domain spanning
residues 60–74 (net charge at pH 7, +4; Table 2). On the
contrary, the greatest anionic density and lowest pI polarized to
the N-terminal hemimer, and particularly to the N-terminal
domain consisting of residues 1–15 (net charge at pH 7, −4;
Table 2). Although no clear trends in hydropathy were detected,
the most terminal domains (e.g., N-terminal residues 1–15, and
C-terminal residues 49–63, 60–74) exhibited greatest hydro-
phobic moments, suggesting they represent the most amphi-
pathic regions of hPF-4 and PMP-1 (Table 2).
3.3. Structural assessment of molecular domains
CD spectrometry was utilized to assess secondary structure
in cPMP walkthrough peptide and hemimer domains (Fig. 1).
These structures were compared to that of human PF-4, or PMP-
1, previously determined by NMR or X-ray spectrometry [36]
or homology modeling [7]. As anticipated, general secondary
structure themes of cPMP peptide domains reflected corre-
sponding regions within native PMP-1 and hPF-4. Such themes
included a relatively extended N-terminal domain (circa
residues 1–23), an interposing anti-parallel β-sheet hairpin
domain (circa residues 24–59), and a C-terminal α-helical
domain (circa residues 60–74). These findings suggest that
walkthrough peptides and cPMP hemimers retained secondary
structural elements of cognate domains previously identified in
full-length PMP-1 [7] and hPF-4 [36].
3.4. Antimicrobial efficacy of molecular domains
The antimicrobial efficacies of study peptides versus a panel
of well-characterized Gram-negative, Gram-positive and fungal
organisms are summarized in Table 3. Consistent with our prior
observations [2,10,37,38], native PMP-1 and hPF-4 molecules
exerted equivalent antimicrobial spectra and efficacies. Impor-
tantly, several functional themes emerged from studies of the
cPMP peptide library in comparison to these molecules. First,
the antimicrobial efficacies of study peptides in radial diffusion
assay were generally greatest against Gram-negative target
organisms (S. typhimurium). Second, in most cases, PMP-1,
hPF-4, or cPMP peptides exerted efficacies corresponding to
established peptide-susceptible or -resistance phenotypes, with
greater efficacies versus the former group. Third, in the cPMP
library, the strongest antimicrobial efficacy localized to the C-terminal hemimer (residues cPMP38–74), and C-terminal
domains 49–63 and 60–74 thereof, representing the corre-
sponding regions of PMP-1 and hPF-4 [7]. For example,
domains cPMP49–63 and cPMP60–74 had greater efficacy versus
either C. albicans strain than did the parent molecule, and
particularly so against the peptide-resistant strain. Interestingly,
a novel antimicrobial domain, cPMP13–27, was localized to the
N-terminal aspect of cPMP. Its antimicrobial efficacy was
greatest versus S. typhimurium, more modest versus C. albicans,
and minimal versus S. aureus (Table 3). However, the N-ter-
minal hemimer (cPMP1–37) encompassing domain cPMP13–27
was devoid of detectable antimicrobial activity against any
organism assayed. Likewise, no antimicrobial efficacy was
detected against study organisms in N-terminal domain 1–15,
or interposing domains 25–39 or 37–51 (Table 3). Com-
plementing the above findings, solution-phase data revealed
highly potent efficacies of the cPMP38–74 at concentrations
descending to 1.25 nmol/ml (Fig. 3). In most cases, cPMP
antimicrobial domains compared favorably in efficacy to
classical peptides, and paralleled those of the peptide mimetic,
RP-1.
The physiological relevance of observed antimicrobial
activities of (cPMP38–74) and (cPMP60–74) were assessed in the
ex vivo biomatrix assay. Importantly, cPMP38–74 demonstrated
significant efficacy in blood matrices, causing decreases of up to
614 M.R. Yeaman et al. / Biochimica et Biophysica Acta 1768 (2007) 609–619log 5 CFU/ml at 10 μg/ml peptide (Fig. 4). Likewise, cPMP60–74
was also highly efficacious in this assay, with a 5 log reduction in
CFU/ml in serum at peptide concentrations as low as 25 μg/ml.
Greatest efficacy was seen in whole blood and serum in co-
incubation studies, with less activity in plasma fractions or after
2 h pre-incubation.Fig. 4. Antimicrobial efficacy of cPMP modular domains in human blood matrices. T
assayed in human blood, plasma, and serum as compared with artificial media (MHB)
target organisms; (B) efficacy of cPMP38–74 pre-incubated in biomatrices or media (
simultaneous co-incubation with the organism; (D) efficacy of cPMP60–74 pre-incub
inocula (INOC) were 105 CFU/ml, and the sensitivity of detection considered to be 0.
in whole blood and plasma matrices, particularly on co-incubation with target org
microbicidal functions of distinct structural domains (e.g., the microbicidal α-helix3.5. Structural correlates of antimicrobial efficacy
Polypeptide composition, sequence, and secondary struc-
ture predictions were compared with antimicrobial efficacy
to identify putative functional correlates of cPMP peptide
domains.he cPMP38–74 (γ-core+ α-helix; [20,62]) or cPMP60–74 (α-helix) domains were
at pH 5.5 and 7.2. (A) efficacy of cPMP38–74 in simultaneous co-incubation with
2 h, 37 °C) prior to introduction of the organism; (C) efficacy of cPMP60–74 in
ated in biomatrices or media prior to introduction of the organism. Initial E. coli
3 log10 CFU/ml. Notably, cPMP38–74 exhibited greater efficacy than cPMP60–74
anisms. This finding supports the hypothesis that γ-core motifs may facilitate
or cPMP60–74) in relevant contexts of infection [8,20,62].
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efficacy
Linear regression analyses revealed direct and inverse
relationships between independent physicochemical parameters
and antimicrobial efficacy (Table 4). Significant direct (r2 >0.5)
correlations were identified associating net cationic charge and
efficacy versus all organisms tested. However, charge density of
a given domain did not achieve significant correlation with
antimicrobial efficacy. Notably, while helical propensity
correlated with efficacy against peptide-susceptible and
-resistant S. aureus, this parameter only correlated with efficacy
against peptide-resistant strains of S. typhimurium or C.
albicans. In contrast, increasing hydrophobic moment, sheet-
ing, and turn propensities yielded significant inverse (r2 <0.05)
correlates of antimicrobial efficacy versus all study organisms
(Table 4). Peptide length, mass, or hydropathy emerged as being
inversely correlated with efficacy solely versus peptide-resistant
counterparts of distinct pathogens (Table 4).
3.5.2. Mapping antimicrobial determinants in cPMP
Glycine scanning enabled localization of charged residues or
groups of residues correlating with efficacy versus peptide-
susceptible or -resistant target organisms (Fig. 5). Notably,
particular charged residues correlated significantly with anti-
microbial efficacy. Although these individual residues are
distributed throughout the molecule, certain amino acid moieties
appeared to be coordinated in 3-dimensional space as governed
by secondary structure. For example, anionic charge clustering
at the N-terminus, and cationic charge concentrated to the C-
terminus and apices of the γ-core motif in hPF-4 and PMP-1,
correlate to efficacy versus peptide-resistant S. typhimuriumTable 4
Univariate analysis of structure–activity relationships in cPMP library peptides
Significant direct (*) correlations (r
2
>0.5) are indicated by black text on gray
shading, and significant inverse (+) correlations (r
2
<0.05) are indicated by white
text on black shading. Note that charge is a uniform direct correlate of efficacy,
whileM
H
, sheeting, and turn propensity are uniform inverse correlates of efficacy
among these peptides. Interesting, some parameters emerged as specific
correlates of efficacy versus some organisms but not others. For example,
helical propensity corresponds to efficacy against both S. aureus strains, but only
peptide-resistant counterparts in S. typhimurium or C. albicans.
aStaphylococcus aureus strain pair as detailed in the legend of Table 3.
bSalmonella typhimurium strain pair as detailed in the legend of Table 3.
cCandida albicans strain pair as detailed in the legend of Table 3.strain 14028R (Fig. 5). In this case, efficacy correlated with
cationic charge concentrated by relatively close proximity of
residues K17, K34, and K64. Conversely, diminishing anionic
potential at positions E31 and D57 also correlated with efficacy.
In contrast to conventional paradigms, increasing anionic charge
localized to residue E73 at the penultimate aspect of the helical
domain also contributed to efficacy against each organism
studied. With few exceptions, correlates of electrostatic position
and efficacy versus susceptible- or resistant-strains were similar
for all organisms tested (Fig. 5).
4. Discussion
4.1. Structural themes of antimicrobial activity in PF-4
kinocidins
Analysis of antimicrobial determinants in hPF-4, PMP-1,
and other PF-4 family kinocidins reveals recurring themes of
structure and activity in these multifunctional host defense
molecules (Fig. 6).
4.2. Physicochemical correlates of antimicrobial efficacy
The physicochemical properties and secondary structural
features of specific cPMP domains yielded insights into the
antimicrobial determinants of PF-4 kinocidins. For exam-
ple, domain cPMP13–27 is proximate to the N-terminus, has
a net charge of +3, and an extended secondary structure.
These features correlate predominantly to efficacy versus S.
typhimurium, but little or no activity against C. albicans
or S. aureus. However, in context of the larger N-terminal
hemimer (residues 1–37), cPMP13–27 is charge-neutralized,
and its antimicrobial activity abrogated. Domain cPMP49–63
also has a net cationic charge (+2), but localizes near the C-
terminus, and has helical and sheet propensity. Because its
charge is similar to domain 13–27, anti-candidal and anti-
staphylococcal efficacies of domain 49–63 likely integrate
secondary structure. The cPMP60–74 domain illustrates a
distinct structure–function theme. Its cationic charge and
amphipathic nature were associated with greater efficacy
versus S. aureus as compared with domains 13–27 or 49–63.
Furthermore, domains cPMP49–63 and cPMP60–74 retained
antimicrobial efficacy within the context of the C-terminal
hemimer (residues 38–74). Likewise, direct antimicrobial
activity has been associated with α-helices in other
microbicidal chemokines [20,21,39,40]. Similar structure–
function correlates have been identified by Lejon and
colleagues for pentadecapeptide congeners derived from
lactoferrin [41].
A particularly important aspect of this study was to
demonstrate antimicrobial efficacy of the C-terminal hemimer
(cPMP38–74) and helix (cPMP60–74) regions in relevant
biological contexts of human blood and blood-derived
matrices. In these physiologically complex settings, these
polypeptides had considerable efficacy against E. coli ML-35
at concentrations descending to 10 μg/ml. This finding was
significant for several reasons. First, it substantiates the
Fig. 5. Positional amino acid residue correlates of antimicrobial efficacy. In these studies, 74 mutant peptides substituting glycine at successive positions along the
cPMP sequence were evaluated in silico for efficacy as compared to the parent molecule. For each organism, parental versus mutant residues are then classified relative
to their contribution to efficacy (relative efficacy ratio [RER]), and highlighted per the following color schema: purple, strong cationic contribution (1.079 to 1.12);
cyan, modest cationic contribution (1.037 to 1.078); orange, modest anionic contribution (0.9192 to 0.8175); red, strong anionic contribution (0.8714 to 0.83); gray, no
significant correlate of efficacy (0.9957 to 1.037). Respective amino- and carboxy-termini are indicated as N and C. The RER for correlates of efficacy are indicated in
parentheses. These experiments reveal residues that are integral to antimicrobial efficacy against a specific organism, between susceptible or resistant strains, and
between different organisms. For clarity, residues contributing significant correlates of efficacy are labeled in the first panel; thereafter, only residues with distinct
impact on efficacy between respective peptide-susceptible and-resistant strains are indicated.
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antimicrobial efficacy in relevant and non-austere conditions.
Second, cPMP38–74 and cPMP60–74 exhibited significant
efficacy in serum fractions on co-incubation, and retained
activity in serum even after 2 h of pre-incubation before
addition of the target pathogen. Prior studies with other
antimicrobial peptides suggest most are substantially reduced
in efficacy or inactivated in serum [42,43], possibly corre-
sponding to their generally poor efficacy in animal models of
hematogenous infection. One potential challenge to furthering
the current line of investigation will be to identify optimal
experimental models that permit detection of antimicrobial
activity in vivo. Nonetheless, the present data are an
extremely important step toward demonstrating the likelihood
that cPMP and related kinocidins or host defense peptides
have unambiguous antimicrobial roles in relevant contexts in
vivo [6,7,20].
4.3. Topographical correlates of antimicrobial efficacy
The above data highlight that antimicrobial efficacy of
polytopic PF-4 or other kinocidins derives from a combination
of independent and collective factors, including charge, steric
bulk and other features. An important aspect of the current
investigation was to gain insight into potential holistic or
autonomous correlates of antimicrobial efficacy in PF-4kinocidins. The present data show that autonomous domains
of these molecules (e.g., the α-helical domain) are capable of
retaining antimicrobial function reflecting their full-length
precursors. Thus, structural contributions to antimicrobial
efficacy and spectra may rely on individual domains. However,
such function may also derive from cooperativity among such
discrete domains in the context of the greater molecule.
Differential antimicrobial efficacies of library peptides also
substantiate roles for distinct spatial arrangements of charge and
steric bulk among functional domains. For example, helical
propensity influences amphipathicity and polar angle, and is
characteristic of classic helical antimicrobial peptides [12–15].
Moreover, polarization of charged residues to the poles of the
hemimer 38–74 is consistent with the pattern of cationic
distribution in γ-core signatures of classical antimicrobial
peptides [6]. This hemimer exerted the greatest efficacy and
spectrum of any peptide tested, with significant activities against
isogenic peptide-susceptible and -resistant strains. It should be
recognized that electrostatic forces have relatively long-range
influences, with energies inversely related to distance. This fact
reinforces the findings that antimicrobial activity of one domain
can be significantly influenced by surrounding molecular
context. An excellent example of this phenomenon is illustrated
in comparing antimicrobial profiles of the N-terminal cPMP1–37
hemimer with its subdomain cPMP13–27. Efficacy of the latter
peptide is abrogated in context of the hemimer. An opposite
Fig. 6. Integrative functional topology model of PF-4 family kinocidins.
Structural domains are represented in topological format: □, extended/turn
domain; △, β-sheet domain; and •, α-helical domain. The CXC, γ-core, and
amphipathic helical motifs are unique to their respective N-terminal, interpos-
ing, and C-terminal domains. Note how the net electrostatic charge is polarized
to termini in the primary structure: the extended and electronegative N-terminus
is isolated from the highly structured and electropositive C-terminal helix by the
interposing anti-parallel β-sheet region. These features illustrate the modular
configurations of PF-4 and related kinocidins. The iconogram depicts the
comparative sequence domains and topology corresponding to efficacy versus
specific pathogens. Relative efficacies of walkthrough peptides versus bacterial
(Gram-positive S. aureus [SA] or Gram-negative S. typhimurium [ST]) or
fungal pathogens (C. albicans [CA]) assayed are indicated by proportionate
area. Filled or shaded topological icons correspond to efficacy versus peptide-
susceptible strains, and open icons correspond to efficacy versus orthologous
peptide-resistant strains. Note the bimodal correlates of topology and efficacy,
particularly versus S. typhimurium. For illustrative purposes, the non-
antimicrobial domains 25–39 and 37–51 have been combined as 25–51 in
this figure.
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of the cationic and α-helical cPMP60–74 appeared to be
augmented in context of antimicrobial contributions by the C-
terminal aspect of its γ-core motif. Thus, the antimicrobial and
chemokine functions of kinocidins are likely conferred by
discrete structural domains as configured to the γ-core motif
[44,45].
4.4. Modular topology of antimicrobial determinants in PF-4
kinocidins
The segregation of functional modules (e.g., extended N-
terminal chemotactic domain versus the C-terminal α-helix)
supports the hypothesis that kinocidins may disassemble into
autonomous and complementary effectors in response to stimuli
(e.g., proteases) in contexts of infection [8]. Examples of
proteolytic processing of kinocidins and classical antimicrobial
peptides include the generation of N-terminal variants of PMP-1
[7], PBP cleavage into consecutive CTAP-3, β-TG, and NAP-2
peptides [2,4], and removal of charge-neutralizing pre–pro- or
pro-piece sequences in defensins [46,47].
The current studies provide evidence that cPMP60–74 can act
independently of the parent molecule, retaining microbicidal
efficacy in vitro and in complex blood and blood-derived
matrices. Whether this domain is liberated in vivo is not known,
however several intriguing observations lend support to thishypothesis. First, the α-helical domain of PMP-1 is routinely
liberated and can be isolated from the parent molecule in
supernatants of thrombin-stimulated platelets (Yeaman et al.,
unpublished). The α-helical domain of PMP-1 and hPF-4
appears to be highly accessible to proteases, whether in
monomeric or multimeric configurations common for this
family [36]. In the monomer, the C-terminal α-helical domain
is tethered to the remainder of the molecule by an exposed
linking region. In the tetrameric configuration, the helical
domains are on the solvent exposed outermost facets of the
multimer. Likewise, recent studies by Braff and colleagues [48]
are consistent with this paradigm, as are reports of antimicrobial
constituents embedded in larger precursor proteins [40,49,50].
Taken together, such observations imply that the α-helical
domain would be accessible and would likely retain its
antimicrobial properties if liberated from the holoprotein.
One finding of particular interest is the marked biophysical
similarity between the α-helical cPMP60–74 domain and many
classical antimicrobial peptides. This fragment is most similar to
themagainin peptides with respect to length, helicity, cationicity,
and amphipathicity; cPMP60–74 is less similar to LL-37 and the
cecropins, which are considerably larger [51]. Based on such
parallels, we predicted significant antimicrobial efficacy would
be associated with this domain. Importantly, the mechanism by
which such α-helical peptides interact with disrupt biological
membranes has been the subject of many excellent studies [52–
57]. Indeed, recent studies have demonstrated that a synthetic
peptide modeled on the cPMP helix recapitulates the anti-
microbial efficacy and mechanism of it native template [58].
4.5. Insights into mechanisms of kinocidin antimicrobial action
and resistance
The current studies also provide insights into the mecha-
nisms of PF-4 family or other kinocidin antimicrobial action and
resistance. Interestingly, the current data differentiate net charge
from charge density as a correlate of antimicrobial efficacy.
Further, several significant correlates of efficacy corresponded
to groups of ionic amino acids. It follows that pathogens use
various mechanisms to increase the net cationic charge of the cell
envelope, thereby reducing affinity and in turn, increasing
resistance to cationic peptides [59,60]. It should be noted, that
although current studies emphasize charge correlates of efficacy,
the potential importance of other physicochemical parameters
(e.g., bulk, hydrophobicity) and conformation to antimicrobial
efficacy should not be underestimated. Thus, while charge may
be critical to initiate interactions between peptide and target
membrane, global biophysical features may be essential for
subsequent mechanisms of peptide microbicidal activity.
An intriguing observation was that differences in peptide
efficacy were generally greater between peptide-resistant and
-susceptible pairs of the same species, than among -susceptible
phenotypes of different species. This finding suggests that
specific peptides exert somewhat different mechanisms of
action against specific organisms, or that distinct organisms
employ different modes of resisting a given peptide. For
example, in S. aureus, decreased charge in the N-terminal
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charged residues in the C-terminal domain were found to be
equally important versus peptide-susceptible and -resistant S.
aureus strains. By comparison, a reduction in charge near the
cationic poles of the γ-core (e.g., K48 and K64 in cPMP)
corresponds to peptide-resistance in C. albicans.
Finally, we recognize the limits of the current investigations.
Using the same basis sets that yielded robust biophysical
correlates of peptide antimicrobial efficacy, we did not identify
correlations between changes in antimicrobial efficacy and (1)
hydrophobic properties or (2) hydrogen bonding potential. Such
a result should not be interpreted to mean these factors are
irrelevant to antimicrobial efficacy [31–33,61,62]. Complex
relationships in peptide structure and antimicrobial activity will
benefit from resolution by increasingly fine-grained basis sets.
Thus, the current studies offer novel insights into the molecular
effectors of host defense, and hold promise for discovery, design,
and development of novel anti-infective agents that are
efficacious against pathogens are increasingly refractory to
conventional therapies.
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